Clinical Diagnosis

Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate

The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease

Kala reaches deal to sell Eysuvis, Inveltys to Alcon

According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.

Ophthalmologists drive efficiency in the surgical suite: Why it matters

Attention to details can help to deliver patients consistent, quality outcomes.